An interventional study of OUD Telehealth Platform in Opioid Use Disorder, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Yale University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Opioid-Related Disorders by Yale University — 20 open to participants now, 24 under way, 1 of them phase 3. Opioid-Related Disorders · Yale University.
Among the 106 studies in Opioid-Related Disorders by Yale University, this one is the 60th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2024, is one of 44 with no phase, and was the 86th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →20 of the 106 studies in Opioid-Related Disorders by Yale University are open now, in 4 countries. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 25–65 · Healthy volunteers
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 26 · Phase 3 7 · Phase 4 9
First in 1988; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 62 across the 94 interventional studies, 108 across the 11 observational. Of the 75 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
10 of the studies in Opioid-Related Disorders by Yale University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06494904Phase 3Yale UniversityStandard Versus High Dose ED-Initiated Buprenorphine Induction | 2027-09 |
| NCT05333341Yale UniversityPain Care at Home to Amplify Function (Pain CHAMP) | 2026-11-30 |
| NCT01730781Yale UniversityImaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning | 2026-12 |
| NCT06160284Yale UniversityExploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) | 2027-01 |
| NCT06207162Yale UniversityLongitudinal Neural Fingerprinting of Opioid-use Trajectories | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 106 studies in Opioid-Related Disorders by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.
The primary objective of the study is to assess effects of enrollment in a comprehensive telehealth platform, in adults with moderate or severe opioid use disorder with a history of at least one opioid overdose. Adults with moderate or severe opioid use disorder with a history of at least one opioid overdose will be enrolled and the primary endpoint will be attendance at first appointment for medication for opioid use disorder at 30 days.
Secondary aims include assessing engagement in the first MOUD appointment at 90 days and self-report of the number of subsequent overdose events at 30 and 90 days. Exploratory aims include feasibility of intervention, readiness and intention to engage in treatment, acceptability and satisfaction of intervention, and comparison of MOUD engagement with data from previous in-person studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be assigned to receive the OUD Telehealth Platform, which will be delivered remotely by research staff.
Behavioral: OUD Telehealth Platform
The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
Attendance for MOUD
Overall attendance will be measured by attendance (yes or no) at the first buprenorphine appointment within 30 days of referral.
Time frame: Up to 30 Days
Overdose Events at 30 Days
A self-report of the number of subsequent overdose events at 30 days.
Time frame: Up to 30 days
Overdose Events at 90 Days
A self-report of the number of subsequent overdose events at 90 days.
Time frame: Up to 90 days
Engagement With MOUD
Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of referral of those participants that engaged with MOUD. This will be collected by self-report survey as yes or no if there was continued engagement with MOUD.
Time frame: Up to 90 days
| Milestone | OUD Telehealth Platform |
|---|---|
| Started | 33 |
| Completed | 31 |
| Not completed | 2 |
| Withdrew: Protocol violation | 2 |
Overall attendance will be measured by attendance (yes or no) at the first buprenorphine appointment within 30 days of referral.
| Participants | OUD Telehealth Platform |
|---|---|
| Yes | 1 |
| No | 24 |
A self-report of the number of subsequent overdose events at 30 days.
| Number of overdose events | OUD Telehealth Platform |
|---|---|
| Overdose Events at 30 Days | 0 (0 to 3) |
A self-report of the number of subsequent overdose events at 90 days.
| Number of overdose events | OUD Telehealth Platform |
|---|---|
| Overdose Events at 90 Days | 0 (0 to 2) |
Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of referral of those participants that engaged with MOUD. This will be collected by self-report survey as yes or no if there was continued engagement with MOUD.
No measurements were reported for this outcome.
Collected over From enrollment until end of follow-up, up to 90 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OUD Telehealth Platform | 0/33 (0%) | 0/33 (0%) | 0/33 (0%) |
| Age, Continuous(year) | OUD Telehealth Platform |
|---|---|
| Mean | 32.1 ± 7.58 |
| Sex: Female, Male(Participants) | OUD Telehealth Platform |
|---|---|
| Female | 14 |
| Male | 19 |
| Race (NIH/OMB)(Participants) | OUD Telehealth Platform |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 25 |
| White | 6 |
| More than one race | 1 |
| Unknown or Not Reported | 1 |
| Ethnicity (NIH/OMB)(Participants) | OUD Telehealth Platform |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 32 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data will be shared as part of the HEAL Initiative Consortium.
Time frame: Following the close of the study and final reporting to funder.
Ran from May 2024 to primary completion in Jul 2025, 14 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 14 months is below that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.